MX2009002571A - Anticuerpos anti-activina a y usos de los mismos. - Google Patents
Anticuerpos anti-activina a y usos de los mismos.Info
- Publication number
- MX2009002571A MX2009002571A MX2009002571A MX2009002571A MX2009002571A MX 2009002571 A MX2009002571 A MX 2009002571A MX 2009002571 A MX2009002571 A MX 2009002571A MX 2009002571 A MX2009002571 A MX 2009002571A MX 2009002571 A MX2009002571 A MX 2009002571A
- Authority
- MX
- Mexico
- Prior art keywords
- activin
- antibodies
- derivatives
- polypeptides
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a composiciones y métodos que se refieren a o derivan de proteínas de enlace a anti-activina A, que incluyen anticuerpos. En modalidades particulares, la descripción proporciona anticuerpos completamente humanos, humanizados y quiméricos anti-activina A, que se enlazan a la activina A humana, fragmentos de enlace a activina A y derivados de tales anticuerpos, y polipéptidos de enlace a activina A que comprenden tales fragmentos. Otras modalidades proporcionan ácidos nucleicos que codifican tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, células que comprenden tales polinucleótidos, métodos para elaborar tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos y métodos para usar tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, que incluyen métodos para tratar o diagnosticar sujetos que tienen trastornos o condiciones relacionadas con activina A, que incluyen, caquexia relacionada con cáncer gonadal, otros cánceres, artritis reumatoide y otras enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84343006P | 2006-09-08 | 2006-09-08 | |
US95665307P | 2007-08-17 | 2007-08-17 | |
PCT/US2007/077923 WO2008031061A2 (en) | 2006-09-08 | 2007-09-07 | Anti-activin a antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009002571A true MX2009002571A (es) | 2009-06-19 |
Family
ID=39103486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009002571A MX2009002571A (es) | 2006-09-08 | 2007-09-07 | Anticuerpos anti-activina a y usos de los mismos. |
Country Status (22)
Country | Link |
---|---|
US (5) | US8309082B2 (es) |
EP (5) | EP3730517A1 (es) |
JP (3) | JP5497438B2 (es) |
AR (1) | AR062703A1 (es) |
AU (1) | AU2007294580C1 (es) |
CA (1) | CA2661878C (es) |
CL (1) | CL2007002567A1 (es) |
CY (2) | CY1116037T1 (es) |
DK (2) | DK2064239T3 (es) |
ES (2) | ES2596184T3 (es) |
HR (2) | HRP20150171T1 (es) |
HU (1) | HUE030463T2 (es) |
LT (1) | LT2559705T (es) |
ME (1) | ME02539B (es) |
MX (1) | MX2009002571A (es) |
PE (1) | PE20080914A1 (es) |
PL (2) | PL2559705T3 (es) |
PT (2) | PT2064239E (es) |
RS (2) | RS53819B1 (es) |
SI (2) | SI2559705T1 (es) |
TW (1) | TW200819466A (es) |
WO (1) | WO2008031061A2 (es) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2332977T3 (en) | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CA3045808C (en) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for promoting bone growth |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
ES2415666T3 (es) | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama |
TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EP2484372A1 (en) * | 2007-02-09 | 2012-08-08 | Acceleron Pharma, Inc. | Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
EP2197421A1 (en) * | 2007-08-31 | 2010-06-23 | Amgen, Inc | Solid-state protein formulation |
CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
HRP20230761T1 (hr) | 2008-08-14 | 2023-10-13 | Acceleron Pharma Inc. | Gdf zamke |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
US8293881B2 (en) | 2009-06-12 | 2012-10-23 | Acceleron Pharma Inc. | Isolated nucleic acid encoding a truncated ActRIIB fusion protein |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
EA032537B1 (ru) | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Способ работы устройства для доставки лекарственного средства |
EP2606066A1 (en) | 2010-08-16 | 2013-06-26 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
EP2638065A4 (en) * | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | ACTRIIA BINDING AGENTS AND USES THEREOF |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
JP6038884B2 (ja) | 2011-04-20 | 2016-12-07 | アムゲン・インコーポレーテッド | 自動式注射装置 |
LT3045189T (lt) | 2011-10-14 | 2018-06-25 | Amgen Inc. | Inžektorius ir surinkimo būdas |
WO2013074557A1 (en) * | 2011-11-14 | 2013-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
SG10201605027XA (en) | 2011-12-19 | 2016-08-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
WO2014071158A1 (en) | 2012-11-02 | 2014-05-08 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
WO2015038888A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
JP7051293B2 (ja) | 2013-10-24 | 2022-04-11 | アムジエン・インコーポレーテツド | 温度感知制御を伴う薬剤送達システム |
KR102458637B1 (ko) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | 주입기 및 조립 방법 |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA3193070A1 (en) | 2014-05-07 | 2015-11-12 | Amgen Inc. | Autoinjector with shock reducing elements |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
SG11201609963PA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Devices and methods for assisting a user of a drug delivery device |
CA2951926C (en) | 2014-06-13 | 2023-01-10 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
MX2017010466A (es) | 2015-02-17 | 2018-06-06 | Amgen Inc | Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas. |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
EA039118B1 (ru) * | 2015-04-01 | 2021-12-07 | Ридженерон Фармасьютикалз, Инк. | Способ лечения прогрессирующей оссифицирующей фибродисплазии |
EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
AU2016255768B2 (en) | 2015-04-29 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
US10618976B2 (en) | 2015-06-16 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP-α agonist antibody |
MY188405A (en) | 2015-08-05 | 2021-12-08 | Janssen Biotech Inc | Anti-cd154 antibodies and methods of using them |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
EP3413912A4 (en) * | 2016-02-11 | 2019-09-25 | The Johns Hopkins University | COMPOSITIONS AND METHODS FOR TARGETING SIGNALING OF ACTIVIN TO TREAT CANCER |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
TN2018000417A1 (en) | 2016-06-14 | 2020-06-15 | Adimab Llc | Anti-coagulation factor xi antibodies. |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
CN114588404A (zh) | 2017-03-28 | 2022-06-07 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突/衝撃の低減 |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
JP2021501616A (ja) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | 配置及び流量検出を備える薬物送達デバイス |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
US11191904B2 (en) | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
MA50904A (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
MX2020008991A (es) | 2018-03-01 | 2020-12-10 | Regeneron Pharma | Metodos para alterar la composicion corporal. |
EA202092286A1 (ru) | 2018-03-26 | 2021-03-18 | Эмджен Инк. | Общие афукозилированные гликоформы антител, полученные в культуре клеток |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
AR116703A1 (es) | 2018-10-15 | 2021-06-02 | Amgen Inc | Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
MX2021007394A (es) | 2018-12-18 | 2021-07-15 | Regeneron Pharma | Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. |
JP2022529319A (ja) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
JP2022534966A (ja) * | 2019-05-30 | 2022-08-04 | アクセレロン ファーマ インコーポレーテッド | Actrii結合性タンパク質及びその使用 |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
EP4034556A1 (en) | 2019-09-26 | 2022-08-03 | Amgen Inc. | Methods of producing antibody compositions |
BR112022013589A2 (pt) | 2020-01-08 | 2022-09-13 | Regeneron Pharma | Tratamento da fibrodisplasia ossificante progressiva |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
IL300362A (en) | 2020-08-20 | 2023-04-01 | Regeneron Pharma | Methods to prevent and treat poor cardiac function and covid-19 with activin A antagonists |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
WO2022140670A2 (en) * | 2020-12-23 | 2022-06-30 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023069421A1 (en) * | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023147107A1 (en) * | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US32011A (en) | 1861-04-09 | Coffee-pot | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
JPH01171495A (ja) * | 1987-12-25 | 1989-07-06 | Ajinomoto Co Inc | モノクローナル抗体及びそれを用いる定量法 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
DE69332981T2 (de) | 1992-10-23 | 2004-05-19 | Immunex Corp., Seattle | Methoden zur herstellung löslicher, oligomerer proteine |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
CA2410912A1 (en) | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
AU2002333241B2 (en) | 2001-07-18 | 2008-09-18 | Merck Patent Gmbh | Glycoprotein VI fusion proteins |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
US7514534B2 (en) | 2003-11-19 | 2009-04-07 | Dyax Corp. | Metalloproteinase-binding proteins |
JP2007530045A (ja) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトox40l(cd134l)特異性モノクローナル抗体 |
EP1796711A2 (en) | 2004-04-22 | 2007-06-20 | Oregon Health and Science University | Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors |
AU2005247871A1 (en) * | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of TGF-beta superfamily receptor signaling |
CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
AU2006208286A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
WO2006096490A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
MX2007013217A (es) | 2005-04-25 | 2008-03-11 | Pfizer | Anticuerpos contra miostatina. |
PL2960253T3 (pl) | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
CN102781518A (zh) | 2009-09-09 | 2012-11-14 | 阿塞勒隆制药公司 | Actriib拮抗剂及其给药和用途 |
WO2011085165A2 (en) | 2010-01-08 | 2011-07-14 | The Brigham And Women's Hospital, Inc. | Ca-125 immune complexes as biomarkers of ovarian cancer |
MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
EP2638065A4 (en) | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | ACTRIIA BINDING AGENTS AND USES THEREOF |
WO2013106715A1 (en) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
-
2007
- 2007-09-04 CL CL200702567A patent/CL2007002567A1/es unknown
- 2007-09-06 TW TW096133216A patent/TW200819466A/zh unknown
- 2007-09-07 EP EP20175809.1A patent/EP3730517A1/en active Pending
- 2007-09-07 ES ES12154124.7T patent/ES2596184T3/es active Active
- 2007-09-07 JP JP2009527594A patent/JP5497438B2/ja active Active
- 2007-09-07 PT PT78420882T patent/PT2064239E/pt unknown
- 2007-09-07 EP EP12154124.7A patent/EP2559705B1/en not_active Revoked
- 2007-09-07 RS RS20150075A patent/RS53819B1/en unknown
- 2007-09-07 WO PCT/US2007/077923 patent/WO2008031061A2/en active Application Filing
- 2007-09-07 ES ES07842088.2T patent/ES2528798T3/es active Active
- 2007-09-07 PL PL12154124T patent/PL2559705T3/pl unknown
- 2007-09-07 PE PE2007001204A patent/PE20080914A1/es not_active Application Discontinuation
- 2007-09-07 EP EP07842088.2A patent/EP2064239B1/en active Active
- 2007-09-07 EP EP16178026.7A patent/EP3133084B1/en active Active
- 2007-09-07 AU AU2007294580A patent/AU2007294580C1/en active Active
- 2007-09-07 SI SI200731843A patent/SI2559705T1/sl unknown
- 2007-09-07 ME MEP-2016-224A patent/ME02539B/me unknown
- 2007-09-07 LT LTEP12154124.7T patent/LT2559705T/lt unknown
- 2007-09-07 MX MX2009002571A patent/MX2009002571A/es active IP Right Grant
- 2007-09-07 SI SI200731605T patent/SI2064239T1/sl unknown
- 2007-09-07 CA CA2661878A patent/CA2661878C/en active Active
- 2007-09-07 HU HUE12154124A patent/HUE030463T2/en unknown
- 2007-09-07 US US11/851,884 patent/US8309082B2/en active Active
- 2007-09-07 DK DK07842088.2T patent/DK2064239T3/da active
- 2007-09-07 PT PT121541247T patent/PT2559705T/pt unknown
- 2007-09-07 EP EP18203136.9A patent/EP3495388A1/en active Pending
- 2007-09-07 AR ARP070103960A patent/AR062703A1/es unknown
- 2007-09-07 PL PL07842088T patent/PL2064239T3/pl unknown
- 2007-09-07 DK DK12154124.7T patent/DK2559705T3/en active
- 2007-09-07 RS RS20160851A patent/RS55100B1/sr unknown
-
2012
- 2012-07-16 US US13/550,447 patent/US8753627B2/en active Active
-
2013
- 2013-02-20 JP JP2013030740A patent/JP5986518B2/ja active Active
-
2014
- 2014-04-24 US US14/260,856 patent/US20150086556A1/en not_active Abandoned
-
2015
- 2015-01-29 CY CY20151100092T patent/CY1116037T1/el unknown
- 2015-02-13 HR HRP20150171TT patent/HRP20150171T1/hr unknown
-
2016
- 2016-05-06 JP JP2016092915A patent/JP6457431B2/ja active Active
- 2016-10-10 HR HRP20161300TT patent/HRP20161300T1/hr unknown
- 2016-10-13 CY CY20161101023T patent/CY1118693T1/el unknown
- 2016-11-08 US US15/346,617 patent/US10100109B2/en active Active
-
2018
- 2018-09-12 US US16/128,831 patent/US11542325B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009002571A (es) | Anticuerpos anti-activina a y usos de los mismos. | |
MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
PH12012501006A1 (en) | Compositions and methods relating to anti-igf-1 receptor antibodies | |
MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
PH12017501025A1 (en) | Antigen binding proteins capable of binding thymic stromal lymphopoietin | |
TN2012000268A1 (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
WO2008108986A3 (en) | Methods and compositions for treating tumor diseases | |
MY162624A (en) | Antibodies directed to her-3 and uses thereof | |
IL198379A (en) | Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease | |
EP3670534A3 (en) | Human fgf receptor and beta-klotho binding proteins | |
EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
WO2008036341A3 (en) | Compositions and methods relating to glucagon receptor antibodies | |
WO2004013180A3 (en) | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof | |
TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
WO2013192596A3 (en) | Antigen binding proteins that bind ccr2 | |
WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
WO2016164657A3 (en) | Antibody therapeutics that bind cd123 | |
WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
WO2014062245A3 (en) | Antigen binding proteins that bind dll-4 | |
WO2016028523A3 (en) | Antigen binding proteins that bind cxcr3 | |
WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
WO2013191982A3 (en) | Antigen binding proteins that bind igf1r | |
AU2016219676A1 (en) | Anti-activin A antibodies and uses thereof | |
WO2006091326A8 (en) | Anti-prl-3 antibodies and methods of use thereof | |
JO3379B1 (ar) | بروتينات ربط الأنتيجين البشري التي تربط b-klotho ومستقبلات fgf ومجموعاتها |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |